 |
When was Crucell founded?
|
 |
Crucell was founded in 2000 following the merger of IntroGene with U-Bysis. |
 |
TOP |
|
When did Crucell become a listed company?
|
|
October 2000. |
|
TOP |
|
On which stock exchanges is Crucell traded?
|
|
Crucell is listed on both Euronext Amsterdam and NASDAQ exchanges under the ticker symbol CRXL, and on the SWX Swiss Exchange under ticker symbol CRX. |
|
TOP |
|
When does Crucell’s fiscal year end?
|
|
Crucell’s fiscal year ends on December 31st. |
|
TOP |
|
What is the date of your next results announcement?
|
|
Please refer to our Event Calendar page. |
|
TOP |
|
When is your Annual General Meeting (AGM) of shareholders?
|
|
Please refer to our Event Calendar page. |
|
TOP |
|
What accounting standards does Crucell report by?
|
|
Crucell reports under US GAAP accounting standards. |
|
TOP |
|
What is Crucell’s official accounting currency?
|
|
Crucell reports in Euro’s. |
|
TOP |
|
How many outstanding shares does Crucell have?
|
|
64,802,325 were outstanding on December 31, 2006. |
|
TOP |
|
I’m considering investing in Crucell. Where can I get financial information about the company?
|
|
You can receive up-to-date information on the Investors section of our website or by contacting Crucell’s Investor Relations department. |
|
TOP |
|
How can I buy Crucell shares?
|
|
Crucell shares are publicly traded and can be purchased through a securities broker. |
|
TOP |
|
Who is Crucell’s independent Auditor?
|
|
Ernst & Young Accountants, based in The Hague, The Netherlands. |
|
TOP |
|
Who are the analysts following Crucell?
|
|
Please refer to the Analyst Coverage section of this website. |
|
TOP |
|
What are Crucell's activities?
|
|
Crucell N.V. is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases. For more information please refer to our About Us section. |
|
TOP |
|
What are Crucell's most important products?
|
|
Crucell’s core portfolio includes a vaccine against hepatitis B, a fully-liquid vaccine against five important childhood diseases, and a virosome-adjuvanted vaccine against influenza. Crucell also markets travel vaccines, such as the only oral anti-typhoid vaccine, an oral cholera vaccine and the only aluminum-free hepatitis A vaccine on the market. The Company has a broad development pipeline, with several Crucell products based on its unique PER.C6® production technology. |
|
TOP |
|
Why are financial details of license agreements often not disclosed?
|
|
Crucell only makes financial details of individual license agreements available in consultation with its licensees or partners. Financial details are often not disclosed for competitive reasons. |
|
TOP |
